Chemesis International Inc. Announces U.S. Multi-State Expansion
Chemesis, Inc. (CSE: CSI) (OTC: CADMF) (FRA:CWAA)
Chemesis International Inc. Announces U.S. Multi-State Expansion
Chemesis will expand its multi-state operations into Michigan, Wisconsin, Missouri, & Illinois
April 29, 2019
Vancouver, BC – Chemesis International Inc. (CSE: CSI) (OTC: CADMF) (FRA: CWAA) (the “Company” or
“Chemesis”), announces it has commenced the process to expand its operations into the Central United
States. The Company will concentrate on establishing operations in Michigan, Wisconsin, Missouri, and
Illinois. The Company is in the application stage in each state and is also in the process of completing due
diligence on assets that include cultivation, extraction, and distribution.
Currently, each state is in different stages of developing its medical and recreational cannabis markets.
The state of Michigan has passed both recreational and medical cannabis laws, and state regulators are
forming recreational cannabis laws with anticipated sales to begin early 2020. In Michigan, Chemesis has
applied for a Hemp Co -Processing License, Hemp Cultivation License, Medical Cannabis Processing
License, and will apply for the Adult Use Cannabis Processing License in Calendar Q4, 2019.
The state of Illinois is developing a medical cannabis program, which allows patients that qualify for certain
medical conditions to obtain cannabis flower and derivatives. The Company will apply for licenses whe n
the state begins accepting applications and is currently evaluating assets and other opportunities in the
state.
In addition, Chemesis will look to build a first mover advantage in Wisconsin, where the state is in the
early stages of forming a basis for legalization. Lastly, the state of Missouri is in the process of shaping a
framework of regulations for a medical cannabis program, and the Company is in the process of applying
for the Medical Processing and Cultivation License.
“Chemesis sees significant opportunities within these states, and it allows the Company to begin building
a presence in the Central and Eastern United States,” said Edgar Montero, CEO of Chemesis. “The
management team has identified opportunities that we believe will provide the Company with significant
exposure in these markets. Chemesis is continuing its efforts to establish itself as a major multi -state
operator with facilities and licenses across the United States.”
On Behalf of The Board of Directors
Edgar Montero
CEO and Director
About Chemesis International Inc.
Chemesis International Inc. is a vertically integrated global leader in the cannabis industry, currently
operating within California, Puerto Rico, and Colombia.
Chemesis, Inc. (CSE: CSI) (OTC: CADMF) (FRA:CWAA)
Chemesis is developing a strong foothold in key markets, from cultivation, to manufacturing, distribution
and retail. Chemesis has facilities in both Puerto Rico and California, allowing for cost effective production
and distribution o f its products. In addition, Chemesis leverages exclusive brands and partnerships and
uses the highest quality extraction methods to provide consumers with quality cannabis products.
Chemesis will add shareholder value by exploring opportunities in emerg ing markets while consistently
delivering quality product to its consumers from seed to sale.
Investor Relations:
1 (604) 398-3378
Social Media:
Chemesis.facebook
Chemesis.twitter
Chemesis.instagram
DesertZen.instagram
CaliforniaSap.instagram
Jay&SB.instagram
Forward-Looking Information: This news release contains "forward -looking information" within the meaning of
applicable securities laws, including in relation to statements regarding the Acquisition, the Buy-Out Transaction, the
anticipated benefits of the Acquisition and the Buy -Out Transaction, respectively, the ability to realize any profits or
increase to profits from its production facilities the expected size of the CBD market, the Company’s ability to increase
production of various cannabidiol products, and generally regarding the business, profi tability, products and future
of the Company’s business, its product offerings and plans for revenue generation, sales and marketing, including
upon completion of the Acquisition and Buy -Out Transaction, respectively. Although the Company believes that the
expectations reflected in the forward -looking information are reasonable, there can be no assurance that such
expectations will prove to be correct. Readers are cautioned not to place undue reliance on forward -looking
information. Such forward -looking statements are subject to risks and uncertainties that may cause actual results,
performance and developments to differ materially from those contemplated by these statements depending on,
among other things, the risks that the Acquisition or Buy -Out Transaction, respectively, will not be completed as
proposed or at all, that the anticipated benefits of the Acquisition or Buy -Out Transaction, respectively, will not
materialize, that its production facilities will not be profitable or increase profitability as expected, that the CBD
market will not expand as anticipated, that the Company will not be able to expand production of CBD products at
the rate anticipated upon closing of the Acquisition or Buy-Out Transaction, respectively (or at all), and generally that
the Company's products and plan will vary from those stated in this news release and the Company may not be able
to carry out its business plans as expected. Except as required by law, the Company expressly disclaims any obligation
and does not intend to update any forward-looking statements or forward-looking information in this news release.
Although the Company believes that the expectations reflected in the forward -looking information are reasonable,
there can be no assurance that such expectations wi ll prove to be correct and makes no reference to profitability
based on sales reported. The statements in this news release are made as of the date of this release.
The CSE has not reviewed, approved or disapproved the content of this press release